David Lassen Shares Insights on Prime/MRx Analysis on GLP-1 for Weight Loss in New Video

October 31, 2023

Earlier this year, Prime Therapeutics/Magellan Rx (Prime/MRx) announced a real-world analysis of glucagon-like peptide-1 agonist (GLP-1a) drugs for weight loss, which found low adherence and increased cost among individuals taking the drug after one year.

WATCH: David Lassen, Chief Clinical Officer at Prime/MRx, shares additional insights on this study

As GLP-1a drugs continue to alter the health care landscape, Prime/MRx subject matter experts will continue keep the pulse on this dynamic trend with trusted data and insights. Check our news page for regular updates.

Related news


July 16, 2024

LISTEN NOW: Beyond the business – Stories of corporate kindness | Pharmacy Friends Podcast

In this episode, we talk about how our employees' help goes beyond our work in health care, aiding in philanthropic efforts


July 12, 2024

August 2024 decisions expected from the FDA

Your monthly synopsis of new drugs expected to hit the market


July 12, 2024

High-Cost Therapy Profile: July 2024

Detailed information about Afamitresgene autoleucel Intravenous (IV)